CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Blue Stream Laboratories for $11.7 million (including $3.0 million in contingent consideration), a transaction completed in January 2016, structured as all cash.
Blue Stream Laboratories operates in Discovery and Safety Assessment (DSA), is based in United States. Charles River Laboratories acquired Blue Stream Laboratories, a Woburn, Massachusetts analytical CRO focused on the characterization of complex biologics and biosimilars, on June 27, 2016 for $11.7 million, a figure that included $3.0 million of contingent consideration. Blue Stream brought recognized expertise in structural and functional protein characterization and in developing and validating cGMP lot-release and stability assays. Folding it in alongside Charles River's discovery, safety assessment and biologics operations extended the company's ability to support biologic and biosimilar programs from characterization through clinical testing and commercialization.
Combining Blue Stream with our existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization. The purchase price for Blue Stream was $11.7 million.
DSA segment, biologics analytical capabilities
Combining Blue Stream with our existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization. The purchase price for Blue Stream was $11.7 million, including $3.0 million in contingent consideration.Charles River FY2016 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.